Prolonged response to osimertinib in three patients with refractory metastatic pancreatic adenocarcinomas with exon 19 deletion: a case report and literature review

Pancreatic cancer is a rising cause of cancer death. Therapeutic options are scarce and of limited efficacy. Up to 26% of patients with metastatic pancreatic cancer could benefit from targeted therapies. We report here for the first time the case of three patients with metastatic pancreatic ductal a...

Full description

Saved in:
Bibliographic Details
Main Authors: Timothée Vigié, Alexandre Perrier, Brice Chanez, Julien De Martino, Loëtitia Favre, Florence Coulet, Jean-Baptiste Bachet, Erell Guillerm, Léo Mas
Format: Article
Language:English
Published: SAGE Publishing 2025-03-01
Series:Therapeutic Advances in Medical Oncology
Online Access:https://doi.org/10.1177/17588359241312078
Tags: Add Tag
No Tags, Be the first to tag this record!